Search Results for: Diabetes

3097 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
SGTA and C1QTNF6 small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha C1q and tumor necrosis factor related protein 6
SRC and WWOX SRC proto-oncogene, non-receptor tyrosine kinase WW domain containing oxidoreductase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Signaling by ERBB4
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and SYK SRC proto-oncogene, non-receptor tyrosine kinase spleen tyrosine kinase
  • Signaling by ERBB2
  • Signaling by the B Cell Receptor (BCR)
  • FCERI mediated MAPK activation
  • Platelet Aggregation (Plug Formation)
  • DAP12 signaling
  • Regulation of signaling by CBL
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • DAP12 interactions
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic Acid
STAT3 and HNF1A signal transducer and activator of transcription 3 (acute-phase response factor) HNF1 homeobox A
  • Signaling by PDGF
  • Signalling by NGF
  • Signaling by FGFR in disease
  • Cellular Senescence
  • Interleukin-6 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by SCF-KIT
  • Signaling by Interleukins
  • Transcriptional regulation of pluripotent stem cells
  • Downstream signal transduction
  • Signaling by FGFR1 mutants
  • Signalling to STAT3
  • Signaling by FGFR mutants
  • Signaling by FGFR1 fusion mutants
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
SYK and HDAC9 spleen tyrosine kinase histone deacetylase 9
  • Signaling by the B Cell Receptor (BCR)
  • FCERI mediated MAPK activation
  • Platelet Aggregation (Plug Formation)
  • DAP12 signaling
  • Regulation of signaling by CBL
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • DAP12 interactions
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic Acid
  • Valproic Acid
SYK and FCRL3 spleen tyrosine kinase Fc receptor-like 3
  • Signaling by the B Cell Receptor (BCR)
  • FCERI mediated MAPK activation
  • Platelet Aggregation (Plug Formation)
  • DAP12 signaling
  • Regulation of signaling by CBL
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • DAP12 interactions
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic Acid
TCF4 and PTF1A transcription factor 4 pancreas specific transcription factor, 1a
  • CDO in myogenesis
  • Myogenesis
  • Regulation of beta-cell development
  • Regulation of gene expression in early pancreatic precursor cells
TCF4 and MSRB3 transcription factor 4 methionine sulfoxide reductase B3
  • CDO in myogenesis
  • Myogenesis
HNF1A and TLE1 HNF1 homeobox A transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • truncations of AMER1 destabilize the destruction complex
  • FBXW7 Mutants and NOTCH1 in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • NOTCH1 Intracellular Domain Regulates Transcription
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by WNT in cancer
HNF1A and RNF14 HNF1 homeobox A ring finger protein 14
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
HNF1A and KAT2B HNF1 homeobox A K(lysine) acetyltransferase 2B
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Clearance
  • HATs acetylate histones
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH1
  • Pre-NOTCH Expression and Processing
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Chromatin organization
  • RNA Polymerase I Transcription
  • Signaling by NOTCH
  • Notch-HLH transcription pathway
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Chromatin modifying enzymes
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
HNF1A and GATA5 HNF1 homeobox A GATA binding protein 5
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
  • Factors involved in megakaryocyte development and platelet production
HNF1B and HIST1H3A HNF1 homeobox B histone cluster 1, H3a
  • Regulation of beta-cell development
  • Regulation of gene expression in early pancreatic precursor cells
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Mitotic Prophase
  • PKMTs methylate histone lysines
  • Regulatory RNA pathways
  • RNA Polymerase I Promoter Clearance
  • HDMs demethylate histones
  • Cellular Senescence
  • Signaling by Wnt
  • HATs acetylate histones
  • M Phase
  • Amyloids
  • NoRC negatively regulates rRNA expression
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • DNA methylation
  • Transcriptional regulation by small RNAs
  • Meiotic recombination
  • HDACs deacetylate histones
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • RNA Polymerase I Transcription
  • formation of the beta-catenin:TCF transactivating complex
  • Epigenetic regulation of gene expression
  • Senescence-Associated Secretory Phenotype (SASP)
  • Negative epigenetic regulation of rRNA expression
  • Factors involved in megakaryocyte development and platelet production
  • PRC2 methylates histones and DNA
  • Cell Cycle, Mitotic
  • RMTs methylate histone arginines
  • Chromatin modifying enzymes
  • Oxidative Stress Induced Senescence
  • TCF dependent signaling in response to WNT
  • RNA Polymerase I Promoter Opening
  • SIRT1 negatively regulates rRNA Expression
  • Signaling by WNT in cancer
  • Condensation of Prophase Chromosomes
TCF7L2 and UBE2I transcription factor 7-like 2 (T-cell specific, HMG-box) ubiquitin-conjugating enzyme E2I
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Post-translational protein modification
  • SUMOylation
  • Meiotic synapsis
  • Processing and activation of SUMO
  • SUMO is transferred from E1 to E2 (UBE2I, UBC9)
TCF7L2 and CTNNBIP1 transcription factor 7-like 2 (T-cell specific, HMG-box) catenin, beta interacting protein 1
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
TCF7L2 and DAZAP2 transcription factor 7-like 2 (T-cell specific, HMG-box) DAZ associated protein 2
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
TERF1 and WFS1 telomeric repeat binding factor (NIMA-interacting) 1 Wolfram syndrome 1 (wolframin)
  • Telomere Maintenance
  • Packaging Of Telomere Ends
  • DNA Damage/Telomere Stress Induced Senescence
  • Chromosome Maintenance
  • Cellular Senescence
  • Meiotic synapsis
  • IRE1alpha activates chaperones
  • XBP1(S) activates chaperone genes
  • Unfolded Protein Response (UPR)
NR2C2 and JAZF1 nuclear receptor subfamily 2, group C, member 2 JAZF zinc finger 1
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
VAV1 and PTPN22 vav 1 guanine nucleotide exchange factor protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • CD28 co-stimulation
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by Interleukins
  • Signaling by VEGF
  • Signaling by Rho GTPases
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • VEGFA-VEGFR2 Pathway
  • Rho GTPase cycle
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • VEGFR2 mediated vascular permeability
  • Regulation of signaling by CBL
  • G alpha (12/13) signalling events
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Cell death signalling via NRAGE, NRIF and NADE
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • p75 NTR receptor-mediated signalling
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • NRAGE signals death through JNK
  • GPVI-mediated activation cascade
  • FCERI mediated Ca+2 mobilization
WFS1 and SMURF1 Wolfram syndrome 1 (wolframin) SMAD specific E3 ubiquitin protein ligase 1
  • IRE1alpha activates chaperones
  • XBP1(S) activates chaperone genes
  • Unfolded Protein Response (UPR)
  • Loss of Function of TGFBR2 in Cancer
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • Signaling by Wnt
  • TGFBR1 LBD Mutants in Cancer
  • Signaling by BMP
  • Hedgehog 'on' state
  • Class I MHC mediated antigen processing & presentation
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Asymmetric localization of PCP proteins
  • Signaling by Hedgehog
  • PCP/CE pathway
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adaptive Immune System

Page 31 out of 155 pages